Indication III
Therapy: Small molecule nasal therapy. Generally regarded as safe (GRAS) designated molecule, currently being used with FDA approval at 20-fold concentration as an excipient in nasal drug delivery.
Status: Clinical –limited clinical trial performed in Europe during COVID-19 pandemic demonstrated 100% efficacy and safety.
Commercial Value: The commercial value of anti-enveloped respiratory virus therapies is exceptionally high, driven by the massive economic burden of infections. The global economic burden of just the influenza (flu virus) is massive, estimated at roughly $570 billion per year, including lost income and mortality costs. In the US alone, the seasonal influenza created a yearly financial toll of $29 billion in 2023-2024